Cantor Fitzgerald initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with a Buy rating. PT $21.

Cantor analyst says, "We consider ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE